November brought four life science IPOs on the NYSE and NASDAQ, giving investors new opportunities to enter the market.
Each month gives investors an opportunity to look back at companies that went public, from the price of their initial public offering (IPO) to what their expertise is.
November brought four life science IPOs, split between the New York Stock Exchange and the NASDAQ. Here the Investing News Network reviews each company for investor consideration.
All numbers and figures were current as of market close on December 3, 2018 and are quoted in US dollars. The companies below were found on the NASDAQ’s IPO list for the month of November.
1. Eton Pharmaceuticals (NASDAQ:ETON)
Market cap: $103.88 million; current share price: $6.20
First on our list of monthly life science IPOs is Eton Pharmaceuticals. The company priced its IPO at $21.6 million on November 12; this consisted of 3.6 million shares priced at $6 each. Eton is a specialty pharmaceutical company working on developing drugs specifically through the US Food and Drug Administration 505(b)(2) pathway. This pathway removes the need for duplicate study information, if it has previously been submitted to the agency.
Along with its eight drug candidates, Eton is pursuing additional growth opportunities.
2. Vapotherm (NYSE:VAPO)
Market cap: $98.65 million; current share price: $20.65
Vapotherm is a respiratory technology company developing invasive support for patients with chronic or acute breathing disorders. The company develops drugs with its proprietary Hi-VNI Technology, which is a fast and safe way to provide treatment for respiratory distress in a single tool.
Through this technology, Vapotherm has developed the Precision Flow Plus and the Precision Flow Heliox, which decrease the work of breathing according to a patient’s prescription. Vapotherm issued the highest IPO on this list at $56 million, or $14 each for 4 million shares.
3. Tiziana Life Sciences (NASDAQ:TLSA)
Market cap: $100.82 million; current share price: $8.44
Tiziana Life Sciences is developing drugs for the treatment of cancers and autoimmune diseases. This goal is being met through a pipeline of two drug programs with a variety of indications, from Crohn’s disease to liver cancer. From this, two indications are moving on to the third phase of development.
The company issued its IPO on the NASDAQ for 442,910 shares at $9.90 each, bringing in $4.3 million.
4. Taiwan Liposome Company (NASDAQ:TLC)
Market cap: $204.30 million; current share price: $6.17
Taiwan Liposome Company (TLC), closes out our list of life science IPOs with a $21.75-million IPO. The company offered over 3.7 million shares priced at $5.80 each. TLC has areas of focus in pain, ophthalmology and oncology with four drug candidates.
The company’s most advanced drug is TLC599, a product in Phase 2 development for osteoarthritis pain. The company has a multitude of technologies for its drugs, including BioSeizer for sustained release, NanoX and antibody-linked nanomedicines for targeted delivery, to name a few.
Don’t forget to follow @INN_LifeScience for real-time updates!
Securities Disclosure: I, Gabrielle Lakusta, hold no direct investment interest in any company mentioned in this article.